利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.022 秒)

    Fructosamine oxidase: antagonists and inhibitors
    3.
    发明授权
    Fructosamine oxidase: antagonists and inhibitors 有权
    果糖胺氧化酶：拮抗剂和抑制剂

    公开(公告)号：US06897243B2

    公开(公告)日：2005-05-24

    申请号：US10226685

    申请日：2002-08-23

    申请人： John Richard Baker ,  Garth J. S. Cooper

    发明人： John Richard Baker ,  Garth J. S. Cooper

    IPC分类号： A61K31/15 ,  A61K31/13

    CPC分类号： A61K31/132 ,  A61K31/15

    摘要： The present invention relates to methods of treating an individual with diabetes mellitus by administering to said individual an effective amount of copper chelators, hydrazine compounds, and/or substrate analogues. The invention also relates to methods of treating an individual with diabetes mellitus by lessening fructosamine odixase activity in said individual. Provided within is disclosure pertaining to treatment, pharmaceutical compositions, dosage ranges, and uses of fructosamine oxidase enzyme inhibitors to lessen fructosamine oxidase activity.

    摘要翻译： 本发明涉及通过向所述个体施用有效量的铜螯合剂，肼化合物和/或底物类似物来治疗患有糖尿病的个体的方法。 本发明还涉及通过减少所述个体中的果糖胺奥曲肽酶活性来治疗患有糖尿病的个体的方法。 其中提供了关于治疗，药物组合物，剂量范围以及果糖胺氧化酶抑制剂用于降低果糖胺氧化酶活性的公开。

    Treatment of type 2 diabetes mellitus
    5.
    发明授权
    Treatment of type 2 diabetes mellitus 失效
    治疗2型糖尿病

    公开(公告)号：US5266561A

    公开(公告)日：1993-11-30

    申请号：US715302

    申请日：1991-06-04

    申请人： Garth J. S. Cooper ,  Howard Greene, Jr.

    发明人： Garth J. S. Cooper ,  Howard Greene, Jr.

    IPC分类号： A61K38/00 ,  A61P3/10 ,  C07K14/575 ,  C07K16/26 ,  C61K37/02 ,  C07K7/06 ,  C07K7/08 ,  C07K7/10

    CPC分类号： C07K16/26 ,  C07K14/575 ,  A61K38/00 ,  Y10S514/866

    摘要： Compounds and methods for blocking the effects of diabetes-associated peptide, or "amylin", a hormone found in the amyloid masses of Type 2 diabetics. This putative hormone has been discovered to function both to inhibit insulin secretion and to inhibit glycogen synthesis. Regulation is accomplished by blocking the binding of amylin or amylin agonists, including calcitonin gene related peptide (CGRP], or biologically active sub-peptides thereof. Inhibitors include substituted peptides or sub-peptides of amylin or CGRP, cross-linked amylin and amylin agonists, synthetic amylin, anti-amylin receptor antibodies and anti-idiotype antibodies, and antibodies directed to amylin and amylin agonist active sites. Other antagonists include organic compounds which can be screened and assayed for anti-amylin effects by disclosed methods.

    摘要翻译： 用于阻断糖尿病相关肽或“胰岛淀粉样多肽”的作用的化合物和方法，其是在2型糖尿病患者的淀粉样蛋白质中发现的激素。 已经发现这种推定的激素既能抑制胰岛素分泌又抑制糖原合成。 调节是通过阻断胰岛淀粉样多肽或胰岛淀粉样多肽激动剂（包括降钙素基因相关肽（CGRP）或其生物活性亚肽）的结合来实现的。抑制剂包括取代的肽或胰岛淀粉样多肽或CGRP的亚肽，交联的胰岛淀粉样多肽和胰岛淀粉样多肽激动剂 ，合成的胰岛淀粉样多肽，抗胰岛淀粉样多肽受体抗体和抗独特型抗体，以及针对胰岛淀粉样多肽和胰岛淀粉样多肽激动剂活性位点的抗体。其它拮抗剂包括通过公开的方法可筛选和测定抗胰淀素作用的有机化合物。

    Preventing and/or treating cardiovascular disease and/or associated heart failure
    9.
    发明授权
    Preventing and/or treating cardiovascular disease and/or associated heart failure 有权
    预防和/或治疗心血管疾病和/或相关的心力衰竭

    公开(公告)号：US08034799B2

    公开(公告)日：2011-10-11

    申请号：US11221298

    申请日：2005-09-07

    申请人： Garth J. S. Cooper ,  John R. Baker

    发明人： Garth J. S. Cooper ,  John R. Baker

    IPC分类号： A61K31/33 ,  A61K31/315 ,  A61K31/195 ,  A61K31/185 ,  A61K31/07 ,  A61K33/32

    CPC分类号： A61K31/197 ,  A61K31/13 ,  A61K31/198 ,  A61K31/30 ,  A61K31/38 ,  A61K31/45 ,  A61K33/30 ,  A61K33/34 ,  A61K45/06

    摘要： Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) toxic, drug-induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the heart, and the central and peripheral nervous systems, (iv) plaque rupture of atheromatous lesions of major blood vessels such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the fermoral arteries and the popliteal arteries, (v) diabetes or the complications of diabetes.

    摘要翻译： 提供了用于减少铜值的方法，例如，治疗，预防或改善组织损伤，例如可能由（i）心脏病（例如心肌病或心肌炎）引起的组织损伤， 例如特发性心肌病，包括糖尿病性心肌病，酒精性心肌病，药物性心肌病，缺血性心肌病，高血压性心肌病等的代谢性心肌病，（ii）主要血管（大血管病）如动脉粥样硬化性疾病如冠状动脉， 颈动脉，脑血管动脉，肾动脉，髂动脉，股动脉和al动脉，（iii）毒性，药物诱导和代谢（包括小血管的高血压和/或糖尿病性疾病（微血管 疾病），例如视网膜小动脉，肾小球小动脉，神经紧张，心脏小动脉和相关毛细血管床 眼睛，肾脏，心脏和中枢和周围神经系统的斑块破裂，（iv）主要血管的动脉粥样硬化病变的斑块破裂，例如主动脉，冠状动脉，颈动脉，脑血管动脉，肾脏 动脉，髂动脉，股动脉和al动脉，（v）糖尿病或糖尿病并发症。

    Amylin activity assays
    10.
    发明授权
    Amylin activity assays 失效
    胰岛淀粉样多肽活性测定

    公开(公告)号：US6048514A

    公开(公告)日：2000-04-11

    申请号：US422747

    申请日：1995-04-14

    申请人： Andrew A. Young ,  Garth J. S. Cooper ,  Timothy J. Rink

    发明人： Andrew A. Young ,  Garth J. S. Cooper ,  Timothy J. Rink

    IPC分类号： A61K49/00 ,  G01N33/66 ,  G01N33/74 ,  A61K38/22 ,  G01N33/15

    CPC分类号： A61K49/0008 ,  A61K49/0004 ,  G01N33/74 ,  G01N33/66 ,  Y10S514/866 ,  Y10S514/884

    摘要： Novel methods for use in identifying or assaying compounds which can simulate the ability of amylin to cause hyperlactemia and hyperglycemia in in vivo biological models, or for use in evaluating the potency of compounds known or suspected to simulate these actions of amylin, which involve introducing test samples into in vivo test systems and determining the presence or amount of a rise in lactate, or determining the presence or amount of a rise in lactate and a rise in glucose, following test sample administration.

    摘要翻译： 用于鉴定或测定化合物的新方法，其可以模拟胰岛淀粉样多肽在体内生物模型中引起高血糖和高血糖的能力，或用于评估已知或怀疑模拟胰岛淀粉样多肽的这些作用的化合物的效力，其涉及引入测试 样品进入体内测试系统并确定乳酸盐升高的存在或数量，或测定样品给药后确定乳酸盐升高的存在或量以及葡萄糖的升高。